Technology
LOGIBODY: The Next Generation of Immunotherapy
The Challenge: Targeting Cancer Without Harming Healthy Cells
Despite significant advancements in oncology, many types of cancer remain difficult to treat. While traditional therapies such as surgery, radiation therapy, and chemotherapy often lack specificity and may damage healthy cells or cause severe side effects, modern immunotherapies such as antibody and cell therapies have already achieved remarkable success. However, these approaches still face several challenges:
✔ Non-specific immune activation: Even modern antibody and cell therapies can attack healthy cells (on-target, off-tumor side effects).
✔ Limited target antigens: Many tumors express antigens that are also present in healthy tissues, making precise targeting difficult.
✔ Uncontrolled immune responses: Immune-stimulating drugs can cause a systemic overactivation of the immune system, leading to severe side effects.
What is a LOGIBODY?
LOGIBODYs (LOGIc-gated antiBODies) are intelligent antibodies that only activate when they detect a specific tumor profile. This ensures a targeted immune response against cancer cells, while healthy cells remain unharmed.
✔ If-Then Logic: Immune activation occurs only when the LOGIBODY binds to a cancer cell.
✔ High Specificity: Tumors are identified based on multiple combined antigens rather than a single target molecule.
✔ Modular Adaptability: LOGIBODYs can be flexibly customized to target different types of cancer.
How Does LOGIBODY Work?
The technology utilizes a DNA-based scaffold that acts as a molecular switch:
Tumor Cell Recognition: LOGIBODY binds to a specific pattern of tumor antigens.
Immune Cell Activation: Only after tumor recognition is the immune-recruitment module released.
Targeted Destruction of Cancer Cells: T cells are precisely activated—without harming healthy cells.
Advantage: Unlike conventional bispecific antibodies, which are constantly active, LOGIBODY activates selectively at the tumor site, reversibly!
Why LOGIBODY? – Key Advantages at a Glance
Higher Specificity, Fewer Side Effects
LOGIBODYs recognize tumors by their unique antigen patterns, minimizing on-target, off-tumor effects.
Controlled Immune Activation
The molecular switch ensures that T cell activation is precisely regulated, preventing uncontrolled immune overstimulation.
Flexible Design for Various Cancer Types
LOGIBODYs are modular—by swapping antibody modules, the platform can be rapidly adapted for new indications.
Vision
If the LOGIBODY technology proves successful in clinical trials, LOGIBODYs could become the next generation of immunotherapy — offering higher precision, fewer side effects, and broader applicability than current antibody therapies.
The future of cancer treatment starts now
– with Plectonic Biotech.